Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) – Equities researchers at Northcoast Research issued their Q3 2016 earnings per share estimates for shares of Zeltiq Aesthetics in a research note issued on Tuesday. Northcoast Research analyst E. Snyder forecasts that the firm will post earnings of $0.07 per share for the quarter. Northcoast Research has a “Buy” rating on the stock. Northcoast Research also issued estimates for Zeltiq Aesthetics’ Q4 2016 earnings at $0.19 EPS, FY2016 earnings at ($0.11) EPS, Q1 2017 earnings at ($0.18) EPS, Q2 2017 earnings at $0.18 EPS, Q3 2017 earnings at $0.17 EPS, Q4 2017 earnings at $0.33 EPS and FY2017 earnings at $0.50 EPS.

ZLTQ has been the subject of several other research reports. Maxim Group boosted their price target on Zeltiq Aesthetics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Tuesday, August 9th. Zacks Investment Research raised Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a research note on Saturday, July 23rd. Stifel Nicolaus boosted their price target on Zeltiq Aesthetics from $38.00 to $52.00 and gave the company a “buy” rating in a research note on Wednesday, September 21st. Brean Capital reissued a “buy” rating on shares of Zeltiq Aesthetics in a research note on Monday, October 24th. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $35.00 price target (up previously from $27.00) on shares of Zeltiq Aesthetics in a research note on Tuesday, August 9th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Zeltiq Aesthetics has a consensus rating of “Buy” and a consensus price target of $42.78.

Earnings History and Estimates for Zeltiq Aesthetics (NASDAQ:ZLTQ)

Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 39.41 on Friday. The company has a market cap of $1.57 billion, a price-to-earnings ratio of 50.85 and a beta of 0.89. Zeltiq Aesthetics has a 52 week low of $18.41 and a 52 week high of $41.48. The company has a 50 day moving average of $37.67 and a 200-day moving average of $33.39.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last issued its quarterly earnings results on Wednesday, November 9th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. The business earned $95.20 million during the quarter, compared to analyst estimates of $90.84 million. Zeltiq Aesthetics had a net margin of 9.48% and a negative return on equity of 6.45%. The business’s revenue was up 55.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.05 earnings per share.

In other news, insider Mark J. Foley sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $37.26, for a total transaction of $372,600.00. Following the completion of the transaction, the insider now directly owns 311,274 shares in the company, valued at $11,598,069.24. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Keith J. Sullivan sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $33.01, for a total value of $264,080.00. Following the transaction, the insider now owns 82,023 shares of the company’s stock, valued at $2,707,579.23. The disclosure for this sale can be found here. Insiders own 15.60% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of ZLTQ. FMR LLC raised its position in shares of Zeltiq Aesthetics by 45.2% in the second quarter. FMR LLC now owns 4,277,811 shares of the company’s stock worth $116,913,000 after buying an additional 1,332,129 shares during the last quarter. BlackRock Fund Advisors raised its position in shares of Zeltiq Aesthetics by 12.2% in the third quarter. BlackRock Fund Advisors now owns 2,579,423 shares of the company’s stock worth $101,165,000 after buying an additional 281,441 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Zeltiq Aesthetics by 30.7% in the second quarter. Point72 Asset Management L.P. now owns 2,219,762 shares of the company’s stock worth $60,666,000 after buying an additional 521,462 shares during the last quarter. Aisling Capital LLC raised its position in shares of Zeltiq Aesthetics by 0.3% in the second quarter. Aisling Capital LLC now owns 2,109,727 shares of the company’s stock worth $57,659,000 after buying an additional 6,199 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Zeltiq Aesthetics by 4.1% in the second quarter. Vanguard Group Inc. now owns 1,569,585 shares of the company’s stock worth $42,897,000 after buying an additional 61,700 shares during the last quarter.

About Zeltiq Aesthetics

ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.

5 Day Chart for NASDAQ:ZLTQ

Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.